This website uses cookies. By using the site you are agreeing to our Privacy Policy.

HOME >> Investor Relations >> Top Message >> Message Archive (April 1, 2015)


To Our Investors - April 1, 2015 -

Japan Tissue Engineering Co., Ltd. (J-TEC) would like to provide a look at its business plans and updates for the new fiscal year.

Business Plans for FY2015 (18th business term)

The regenerative medicine environment in Japan continues to experience a tailwind. The government has guaranteed a large part of its budget this fiscal year for basic research into regenerative medicine, including into iPS cells. The enactment of two regenerative medicine-related laws infused the industry with energy. Competitors are working on product commercialization, with the benchmark being the approved products JACE and JACC (both from our company). With these changes in the environment, FY2015 promises to be a full year for J-TEC.

Our most important goal for FY2015 is to increase sales for autologous cultured cartilage JACC. We trained medical institutions and then increased the number of JACC treatments in FY2014. Our specialized culture facility for JACC (on our fourth floor) is almost complete, and final preparations are underway. By utilizing promotion tools effectively we will expand use of JACC both safely and steadily. Also, in FY2015, we will offer a new consulting service for medical institutions offering regenerative medicine under the Act on the Safety of Regenerative Medicine, and a contract cell culturing business.

On the product development side, in addition to expanding clinical trials as necessary for autologous cultured corneal epithelium and autologous cultured epidermis JACE, we are actively pursuing product development for several new products, including a contract development from Fujifilm.

Meanwhile, we are also facing several challenges. We will continue to grow the good parts of our carefully built up “J-TEC Model” (our business model), but I believe that in order for us to move forward we must also bravely face changes. As such, J-TEC as a manufacturer will work on making improvements and transformations.

As the external environment changes dramatically, we will build up our stock of success stories, and through a full FY2015, we will lay the path to profitability.

Eight New Team Members

J-TEC hires new graduates every year, which is rare among Japanese bio-venture companies. This year, we are joined by eight new team members. We are working on creating the regenerative medicine industry, and that begins with human development. Company management requires many kinds of management resources, and particularly for venture companies financial and human resources are important to carry out management strategy. Also, since we are a manufacturer, passing on our manufacturing techniques is essential at a manufacturing site. As a result, more than half of our executive team is from outside of Aichi Prefecture, and more than 60% of the team is now female. Together with our eight new team members, we at J-TEC aim to industrialize regenerative medicine.

New team members


April 1, 2015
Yosuke Ozawa
President & CEO
Japan Tissue Engineering Co., Ltd.